PT  - JOURNAL ARTICLE
AU  - AYUMI TAKAOKA
AU  - TOSHIAKI ISHIKAWA
AU  - SATOSHI OKAZAKI
AU  - SHUICHI WATANABE
AU  - FUYUKI MIYA
AU  - TATSUHIKO TSUNODA
AU  - AKIFUMI KIKUCHI
AU  - SHINICHI YAMAUCHI
AU  - TAKATOSHI MATSUYAMA
AU  - MASANORI TOKUNAGA
AU  - HIROYUKI UETAKE
AU  - YUSUKE KINUGASA
TI  - ELF3 Overexpression as Prognostic Biomarker for Recurrence of Stage II Colorectal Cancer
AID  - 10.21873/invivo.12248
DP  - 2021 Jan 01
TA  - In Vivo
PG  - 191--201
VI  - 35
IP  - 1
4099  - http://iv.iiarjournals.org/content/35/1/191.short
4100  - http://iv.iiarjournals.org/content/35/1/191.full
SO  - In Vivo2021 Jan 01; 35
AB  - Background/Aim: Adjuvant chemotherapy for high-risk Stage II colorectal cancer (CRC) is weakly recommended; however, no consensus exists on “high-risk” definition. Prognostic biomarker identification is important for selecting patients with poor prognosis who may benefit from adjuvant chemotherapy. Materials and Methods: Using Microarray data analyses, ELF3 was identified as a candidate gene highly expressed in Stage II CRC with distant recurrences. ELF3 mRNA expression in 168 Stage II CRC patients was subjected to quantitative RT-PCR analysis and ELF3 protein expression in 185 patients was quantified by immunohistochemical analysis. The relationship between mRNA and protein expression levels and patient characteristics were also investigated. Results: The overall recurrence rate and relapse-free survival were significantly poorer in the ELF3 high-expression than the low-expression group at the mRNA and protein levels. High ELF3 mRNA and protein expression levels were independent poor prognostic factors. Conclusion: High ELF3 expression was associated with recurrence of Stage II.